Production of Pharmaceuticals

Genetically engineered E. coli is used because it can be programmed to express the human proinsulin gene efficiently. The bacteria are cost-effective to culture at scale, grow rapidly in controlled bioreactors, and produce high yields of recombinant protein. This makes E. coli the preferred organism for large-scale pharmaceutical insulin production.

Proinsulin accumulates as insoluble inclusion bodies within E. coli cells after chemical induction. These protein aggregates concentrate the target product, simplifying downstream isolation. Cells are harvested and lysed to release inclusion bodies, which are then solubilized and processed further to extract and refold the proinsulin into its active form.

Fed-batch culture allows controlled nutrient feeding to maintain optimal cell density and growth conditions in large bioreactors. Starter cultures are progressively scaled from small flasks to a 50,000-L bioreactor, where temperature, pH, and air saturation are tightly regulated at 37°C, pH 7, and ~30% air saturation to maximize proinsulin yield.

Oxidative sulfitolysis with sodium sulfite and sodium tetrathionate temporarily blocks exposed cysteine residues, preventing incorrect disulfide bond formation during refolding. This controlled chemical modification at pH 9.5–11 and 25–37°C ensures that when the proinsulin refolds, disulfide bonds form correctly, restoring the native structure required for biological activity.

Refolded proinsulin is enzymatically processed using trypsin and carboxypeptidase B to remove the C-peptide linker, generating active human insulin. The insulin is then purified using ion-exchange, size-exclusion, and reverse-phase chromatography to achieve pharmaceutical-grade purity before crystallization with zinc and formulation into injectable products.

The bioreactor maintains strict environmental parameters including temperature at 37°C, pH at 7, and air saturation at approximately 30%. Nutrient feeding is controlled throughout growth, and a chemical inducer is added at optimal cell density to trigger proinsulin expression. These regulated conditions maximize cell growth and protein yield in the large-scale production system.

A chemical inducer activates the tryptophan promoter controlling the proinsulin gene, switching expression from repressed to active. Once cells reach optimal density in the bioreactor, induction triggers rapid proinsulin accumulation as inclusion bodies. This inducible system allows precise timing of protein production to maximize yield and cell viability during fermentation.